Medicine and Dentistry
Sorafenib
100%
Mitogen-Activated Protein Kinase
100%
Radiosensitivity
100%
Mitogen Activated Protein Kinase Kinase
100%
Cell Signaling Pathway
100%
Hepatocellular Carcinoma Cell Line
100%
Cells
26%
Radiosensitization
26%
Hepatocellular Carcinoma
20%
Double Stranded DNA
20%
Cell Viability
20%
Therapeutic Procedure
13%
Protein Kinase B
13%
Kinase Signaling
13%
Clonogenic Assay
13%
Malignant Neoplasm
6%
Association
6%
Overall Survival
6%
Irradiation
6%
Signal Transduction
6%
Immunofluorescence
6%
Radiation Therapy
6%
Western Blot
6%
Phosphoinositide 3-Kinase
6%
Carcinoma Cell
6%
Phosphorylation
6%
MTT Assay
6%
LY294002
6%
3 (4,5 Dimethyl 2 Thiazolyl) 2,5 Diphenyltetrazolium Bromide
6%
U0126
6%
Sensitivity Enhancement
6%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Sorafenib
100%
Mitogen Activated Protein Kinase
100%
Mitogen Activated Protein Kinase Kinase
100%
Cell Viability
20%
Double Stranded DNA
20%
Protein Kinase B
13%
Malignant Neoplasm
6%
Protein
6%
Overall Survival
6%
Irradiation
6%
Phosphatidylinositol 3 Kinase
6%
2 Morpholino 8 Phenylchromone
6%
3 (4,5 Dimethyl 2 Thiazolyl) 2,5 Diphenyltetrazolium Bromide
6%
1,4 Diamino 1,4 Bis(2 Aminophenylthio) 2,3 Dicyanobutadiene
6%